<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419600</url>
  </required_header>
  <id_info>
    <org_study_id>D1883C00006</org_study_id>
    <secondary_id>2011-002412-87</secondary_id>
    <nct_id>NCT01419600</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD8683 After Single Ascending Doses Administered Via Turbuhaler in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of increasing single doses of AZD8683 administered via inhalation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study
      to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of inhaled AZD8683
      after Single Ascending Doses administered via Turbuhaler in Healthy Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety of AZD8683 by assessing the frequency of adverse events</measure>
    <time_frame>Adverse events are captured from screening and captured on each clinic day and on the follow up day.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of AZD8683 by assessing a panel of laboratory safety assessments</measure>
    <time_frame>Lab safety assessments are taken at screening, pre-dose on day 1 and then 24 hours, and 48 hours post-dose and again on follow up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of AZD8683 by assessing dECG.</measure>
    <time_frame>dECG is conducted pre-dose and then 15 minutes, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 8 hours 12 hours, 24 hours and 48 hours post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of AZD8683 by assessing physical examination</measure>
    <time_frame>A physical examination is conducted at screening, day -1, day 3 and again at follow-up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of AZD8683 by assessing vital signs (BP and pulse)</measure>
    <time_frame>Vital signs are measured at screening, pre-dose and then 15 minutes, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours and 48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety of AZD8683 by assessing Spirometry</measure>
    <time_frame>Spirometry is conducted pre-dose and at 5 minutes, 15 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum plasma concentration (Cmax) will be determined for AZD8683</measure>
    <time_frame>pre-dose and than 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to Cmax (tmax) will be determined for AZD8683</measure>
    <time_frame>pre-dose and then 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Terminal half-life (t1/2z)will be determined for the AZD8683</measure>
    <time_frame>pre-dose and then 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to 24 h (AUC(0-24))</measure>
    <time_frame>pre-dose and than 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to 48 h (AUC(0-48)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to the time of the last measurable concentration (AUC(0-t))</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to infinity (AUC)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma clearance (CL/F)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during terminal phase (Vz/F)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of drug excreted unchanged into urine in a collection interval (Ae)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of dose excreted unchanged in urine (Ae/Dose)</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours and 120 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of drug excreted unchanged into urine from zero to time 48 h (Ae(0-48))</measure>
    <time_frame>0 minutes, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacodynamics (PD) of inhaled single ascending doses of AZD8683 in healthy subjects including the Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>Spirometry for FEV1 is conducted pre-dose and at 5 minutes, 15 minutes, 1 hour, 2 hours and 4 hourspost dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacodynamics (PD) of inhaled single ascending doses of AZD8683 in healthy subjects the Forced Vital Capacity (FVC) parameter</measure>
    <time_frame>Spirometry for FVC is conducted pre-dose and at 5 minutes, 15 minutes, 1 hour, 2 hours and 4 hourspost dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacodynamics (PD) of inhaled single ascending doses of AZD8683 in healthy subjects the heart rate will be measured</measure>
    <time_frame>Heart rate is measured pre-dose and then at 15 minutes, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours and 4 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1 - 4, single ascending dose AZD 8683</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1-4 single ascending dose Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8683</intervention_name>
    <description>Single Dose Inhaled IMP via Turbuhaler</description>
    <arm_group_label>Group 1 - 4, single ascending dose AZD 8683</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match</intervention_name>
    <description>Single dose Inhaled Placebo via Turbuhaler</description>
    <arm_group_label>Group 1-4 single ascending dose Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures Healthy male subjects aged 18

          -  45 years with suitable veins for cannulation or repeated venepuncture

          -  Male subjects should be willing to use barrier contraception ie, condoms and
             spermicide, from the day of dosing until at least 3 months after dosing with the
             investigational product

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 inclusive and weigh at least 50
             kg and no more than 100 kg inclusive

        Exclusion Criteria:

          -  History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any
             other condition known to interfere with absorption, distribution, metabolism or
             excretion of drugs

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of the investigational product

          -  Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

               -  Systolic blood pressure &gt;140 mm Hg

               -  Diastolic blood pressure &gt;90 mm Hg

               -  Heart rate &lt;40 or &gt;85 beats per minute Any clinically important abnormalities in
                  rhythm, conduction or morphology of resting ECG. This includes subjects with any
                  of the following:

               -  PR(PQ) interval prolongation &gt;200 ms or dropped beats (single non conducted
                  P-waves) based on screening or Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms
                  or family history of long QT syndrome
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darren Wilbraham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>July 2, 2012</last_update_submitted>
  <last_update_submitted_qc>July 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>single ascending dose study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

